First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J. Sullivan(Dana-Farber Cancer Institute), Bob T. Li(Memorial Sloan Kettering Cancer Center), Mario Sznol(Yale University), Andrea Wang‐Gillam(Washington University in St. Louis), Keith T. Flaherty(Cancer Research Center), Anna M. Varghese(Memorial Sloan Kettering Cancer Center), Sapna P. Patel(JSS Dental College and Hospital), Gary DeCrescenzo(Phenomenome Discoveries (Canada)), Mary Varterasian(Phenomenome Discoveries (Canada)), Geoffrey I. Shapiro(Brigham and Women's Hospital), Deborah Jean Lee Wong(University of California, Los Angeles), Anna Groover(Phenomenome Discoveries (Canada)), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Saurabh Saha(Phenomenome Discoveries (Canada)), Elizabeth I. Buchbinder(Massachusetts General Hospital), David M. Hyman(Memorial Sloan Kettering Cancer Center), Filip Jankú(The University of Texas MD Anderson Cancer Center), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Antoni Ribas(University of California, Los Angeles), Richard D. Carvajal(Northwell Health), Vicki L. Keedy(Vanderbilt University Medical Center), Jeffrey R. Infante(Cancer Research Center), James W. Mier(Hadassah Medical Center), Mario E. Lacouture(Garden City Community College), Dean J. Welsch(Phenomenome Discoveries (Canada)), Manish R. Patel(Sarah Cannon)
Cited by 418
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k